Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
- 19 February 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 397 (10277), 879-880
- https://doi.org/10.1016/s0140-6736(21)00455-4
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 PandemicInternational Journal of Molecular Sciences, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020